Drug Trial Radar · NCT07266428
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Ottimo Pharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.
Conditions
- Advanced Solid Tumors
Interventions
OTP-01Drug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 and Phase 2A: Frequency and Severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: C1D1 through EoT (up to 36 months)
- Phase 2A - Progression Free Survival (PFS)Time frame: C1D1 through EoT (up to 36 months)
- Phase 2A - Disease Control Rate (DCR)Time frame: C1D1 through EoT (up to 36 months)
- Phase 2A - Duration of Response (DOR)Time frame: C1D1 through EoT (up to 36 months)
- Phase 2A - Objective Response Rate (ORR)Time frame: C1D1 through EoT (up to 36 months)
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan · Recruiting
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
Cancer Research SA
Adelaide, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, Australia · Recruiting
Linear Clinical Research
Nedlands, Australia · Recruiting
Oncosite - Centro de Pesquisa Clinica Em Oncologia
Ijuí, Brazil · Recruiting
Centro Gaucho Integrado
Porto Alegre, Brazil · Recruiting
Instituto do Cancer do Estado de São Paulo (ICESP)
São Paulo, Brazil · Recruiting
Oncostar
São Paulo, Brazil · Recruiting
START Dublin Early Phase Clinical Trials Unit
Dublin, Ireland · Recruiting
Auckland City Hospital
Auckland, New Zealand · Recruiting
Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)
Lisbon, Portugal · Recruiting
NEXT Oncology Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
NEXT Oncology Madrid
Madrid, Spain · Recruiting
START - Rioja
Rioja, Spain · Recruiting
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye) · Recruiting
Ankara Oncology Training and Research Hospital
Ankara, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.